{"id":"ava","safety":{"commonSideEffects":[{"rate":"30-60","effect":"Local injection site reactions (erythema, edema, pain)"},{"rate":"10-30","effect":"Myalgia"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"241f4334-2e88-4f7b-a0c7-c93da9f5086c","title":"AVANT 70% ALCOHOL GEL (ALCOHOL) GEL [B4 SOAP LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AVA (Anthrax Vaccine Adsorbed) contains inactivated anthrax spores and cell-free filtrate antigen adsorbed to aluminum hydroxide. It works by inducing both humoral and cell-mediated immune responses that generate protective antibodies against protective antigen (PA) and other anthrax virulence factors, preventing disease establishment and progression if exposure occurs.","oneSentence":"AVA is an anthrax vaccine that stimulates the immune system to produce antibodies against anthrax toxins, providing protection against infection by Bacillus anthracis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:29.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of anthrax infection in persons at high risk of exposure"},{"name":"Post-exposure prophylaxis following confirmed or suspected anthrax exposure"}]},"trialDetails":[{"nctId":"NCT06895759","phase":"NA","title":"Impact of CO2 Absorption on Gas Exchange and Ventilation Patterns While Breathing Into a Snow Air Pocket","status":"COMPLETED","sponsor":"Institute of Mountain Emergency Medicine","startDate":"2025-03-20","conditions":"Avalanche Burial","enrollment":22},{"nctId":"NCT00050310","phase":"","title":"Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-10-31","conditions":"Anthrax, Bacillus Infections","enrollment":200},{"nctId":"NCT07447128","phase":"","title":"Prospective Analysis of Arteriovenous Access (AVA) Use for Continuous Renal Replacement Therapy (CRRT)","status":"NOT_YET_RECRUITING","sponsor":"East Carolina University","startDate":"2026-03","conditions":"Continuous Renal Replacement Therapy (CRRT), End Stage Kidney Disease (ESRD)","enrollment":50},{"nctId":"NCT05381753","phase":"","title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","status":"COMPLETED","sponsor":"CStone Pharmaceuticals","startDate":"2022-08-29","conditions":"Gastrointestinal Stromal Tumors","enrollment":61},{"nctId":"NCT07342842","phase":"","title":"Comparison of the Ultrasonic Cardiac Output Monitor and Echocardiography for Hemodynamic Assessment in Pediatric Anesthesia","status":"COMPLETED","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2021-03-01","conditions":"USCOM, Echocardiography, Echocardiography Guided Fluid Management","enrollment":57},{"nctId":"NCT07168564","phase":"NA","title":"Post Marketing Clinical Study on the Efficacy of Lenses From a New Prescription Protocol","status":"RECRUITING","sponsor":"Essilor International","startDate":"2025-09-22","conditions":"Ametropia, Refractive Error","enrollment":120},{"nctId":"NCT04067011","phase":"PHASE2","title":"Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-08-12","conditions":"Anthrax","enrollment":210},{"nctId":"NCT01753115","phase":"PHASE2","title":"Ciprofloxacin BioThrax Co-Administration Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2012-12","conditions":"Anthrax","enrollment":154},{"nctId":"NCT05996393","phase":"PHASE4","title":"CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2023-09-15","conditions":"Aplastic Anemia","enrollment":86},{"nctId":"NCT06894550","phase":"NA","title":"Short-term Exposure to High Altitude in Patients With Asymptomatic Aortic Stenosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-04-01","conditions":"Aortic Stenosis, Altitude","enrollment":60},{"nctId":"NCT04660201","phase":"PHASE1","title":"Anthrax AV7909 Liquid vs Lyophilized","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-25","conditions":"Anthrax, Anthrax Immunisation","enrollment":41},{"nctId":"NCT00119067","phase":"PHASE4","title":"Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2002-05","conditions":"Healthy","enrollment":1564},{"nctId":"NCT04636892","phase":"NA","title":"Evaluating Infrasonic Hemodynography","status":"RECRUITING","sponsor":"Scripps Health","startDate":"2021-01-04","conditions":"Aortic Stenosis, Mitral Regurgitation, Pulmonary Hypertension","enrollment":25},{"nctId":"NCT01491607","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2011-11","conditions":"Anthrax","enrollment":200},{"nctId":"NCT03877926","phase":"PHASE3","title":"VELOCITY: An Anthrax Vaccine Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-03-11","conditions":"Anthrax","enrollment":3862},{"nctId":"NCT01263691","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2010-12","conditions":"Bacillus Anthracis (Anthrax) Infection","enrollment":105},{"nctId":"NCT02339155","phase":"PHASE4","title":"Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2015-02-24","conditions":"Infections, Bacterial","enrollment":573},{"nctId":"NCT01979406","phase":"PHASE1","title":"A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2013-11","conditions":"Anthrax Infection","enrollment":120},{"nctId":"NCT01770743","phase":"PHASE2","title":"A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2013-01","conditions":"Anthrax","enrollment":168},{"nctId":"NCT06004752","phase":"PHASE2","title":"Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08-17","conditions":"Aplastic Anemia","enrollment":30},{"nctId":"NCT05310461","phase":"NA","title":"Early Versus Deferred Aortic Valve Replacement in Patients With Moderate Aortic Stenosis and Mitral Regurgitation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2022-08-17","conditions":"Aortic Valve Replacement in Patients With Moderate Aortic Stenosis Combined With Mitral Regurgitation","enrollment":80},{"nctId":"NCT03084510","phase":"NA","title":"REPRISE China - Clinical Evaluation in China","status":"WITHDRAWN","sponsor":"Boston Scientific Corporation","startDate":"2020-02-28","conditions":"Stenoses, Aortic Valve","enrollment":""},{"nctId":"NCT04333875","phase":"","title":"Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2020-03-20","conditions":"Aortic Valve Stenosis","enrollment":71},{"nctId":"NCT05720234","phase":"PHASE2","title":"Avatrombopag Combined With IST as First-line Treatment for SAA","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-11-10","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT05654194","phase":"PHASE3","title":"Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-31","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT04053192","phase":"","title":"Evaluation of BAV in Different Hemodynamic Entities of Severe AS","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2018-06-01","conditions":"Aortic Valve Stenosis","enrollment":166},{"nctId":"NCT03161873","phase":"","title":"Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-11","conditions":"Fertility Disorders, Early Pregnancy","enrollment":194},{"nctId":"NCT02031302","phase":"","title":"RESPOND Post Market Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2014-05-27","conditions":"Aortic Valve Stenosis","enrollment":1064},{"nctId":"NCT05015829","phase":"","title":"Diagnostic Impact of Low-dose Dobutamine Echocardiography in Low-flow Low-gradient Aortic Stenosis","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2019-09-01","conditions":"Aortic Valve Stenosis, Valvular Stenosis, Valvular Heart Disease","enrollment":150},{"nctId":"NCT04009720","phase":"","title":"RESPOND EDGE Post Market Study","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2019-10-11","conditions":"Aortic Valve Stenosis","enrollment":200},{"nctId":"NCT04896528","phase":"PHASE2","title":"Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia, Avatrombopag","enrollment":30},{"nctId":"NCT02584946","phase":"NA","title":"Avenanthramides and Exercise","status":"COMPLETED","sponsor":"PepsiCo Global R&D","startDate":"2016-03-02","conditions":"Avenanthramides","enrollment":24},{"nctId":"NCT02415374","phase":"NA","title":"Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical","status":"COMPLETED","sponsor":"PepsiCo Global R&D","startDate":"2015-01-05","conditions":"Bioavailability, Metabolism, Avenanthramides","enrollment":16},{"nctId":"NCT04065464","phase":"","title":"TRACY - Track My Cycle","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2019-07-03","conditions":"Fertility Monitor, Cycle Tracking","enrollment":303},{"nctId":"NCT04537585","phase":"NA","title":"COVID-19: Collecting Measurements of Renin-angiotensin-system Markers, Such as Angiotensin-2 and Angiotensin 1-7","status":"UNKNOWN","sponsor":"Guyguy K Tshima, MD","startDate":"2020-11","conditions":"Covid19","enrollment":2000},{"nctId":"NCT03518125","phase":"PHASE2","title":"BARDA Securing Anthrax Immunity For the Elderly","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2018-05-09","conditions":"Anthrax","enrollment":305},{"nctId":"NCT01965041","phase":"NA","title":"Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy","status":"WITHDRAWN","sponsor":"Manhattan Eye, Ear & Throat Hospital","startDate":"2013-10","conditions":"Pattern Dystrophy of Macula","enrollment":""},{"nctId":"NCT01641991","phase":"PHASE4","title":"Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-07","conditions":"Bacillus Anthracis (Anthrax)","enrollment":328},{"nctId":"NCT00133484","phase":"PHASE2","title":"UMD rPA Regimen Trial in Adults","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Bacillus Anthracis (Anthrax)","enrollment":270},{"nctId":"NCT00170469","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed","status":"COMPLETED","sponsor":"PharmAthene UK Limited","startDate":"2005-03","conditions":"Bacillus Anthracis (Anthrax)","enrollment":226}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"PAIN"},{"count":8,"reaction":"HYPOTENSION"},{"count":7,"reaction":"CONSTIPATION"},{"count":7,"reaction":"FALL"},{"count":6,"reaction":"BALANCE DISORDER"},{"count":6,"reaction":"BLOOD CALCIUM DECREASED"},{"count":6,"reaction":"COGNITIVE DISORDER"},{"count":6,"reaction":"CREATININE RENAL CLEARANCE DECREASED"},{"count":6,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"},{"count":6,"reaction":"FATIGUE"}],"_approvalHistory":[],"publicationCount":1957,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anthrax vaccine adsorbed (BioThrax)"],"phase":"marketed","status":"active","brandName":"AVA","genericName":"AVA","companyName":"Emergent BioSolutions","companyId":"emergent-biosolutions","modality":"Biologic","firstApprovalDate":"","aiSummary":"AVA is an anthrax vaccine that stimulates the immune system to produce antibodies against anthrax toxins, providing protection against infection by Bacillus anthracis. Used for Prevention of anthrax disease in persons at high risk of exposure (occupational, military, or post-exposure prophylaxis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}